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A B S T R A C T
Foot-and-mouth disease (FMD) is one of the most devastating diseases affecting livestock. Since vaccines fail to
provide protection until seven days post-vaccination, the application of anti-viral molecules is imperative for
suppressing the spread of FMDV prior to development of an adaptive immune response. Interferons (IFNs) are
effective for the host to fight FMDV infections; however, a novel type I IFNs, interferon delta (IFN-δ), has not
been investigated for their antiviral effects against this virus. Thus, this study investigated FMDV infection, upon
pre- and post-treatment with PoIFN-δ8. Real-time quantitative PCR was used to quantify the expression levels of
IFN-stimulated genes (ISGs), including ISG15, OAS1, PKR, and Mx1. Results showed the PoIFN-δ8 lacking its
signal sequence was efficiently expressed in Escherichia coli, and the purified recombinant PoIFN-δ8 exerted a
significantly protective effect against two different serotypes of FMDV in IBRS-2 cells. In addition, PoIFN-δ8
induced the expression of IFN-stimulated genes. These findings highlight the significance of PoIFN-δ might serve
as an antiviral agent for the prevention of FMDV in pigs and will stimulate the study of exploiting the potential
biological functions of IFN-δ in the future.
1. Introduction
Interferons (IFNs) are the first line of defense against viral infec-
tions. There are three groups of IFNs (type I, II and III) based on dif-
ferences in the structure of their cell surface receptors [1]. Type I IFNs
are the largest family and are the prominent IFNs responding to viral
infections. In spite of this, studies of type I IFNs are still mainly focused
on IFN-α and β, while knowledge of other subtypes is limited. As one of
the members of type I IFNs, IFN-δ was first identified by Lefevre and
Boulay in 1993 [2]. Subsequently, Cochet et al. reported several IFN-δ-
related sequences by genomic database screening and indicated that
IFN-δ exists in numerous cloven-hoofed animals and form a distinct
cluster in the genome [3]. Expressing in the porcine blastocyst during
implantation, IFN-δ was suggested have specific functions during
pregnancy [2,4,5]. Similar to other type I IFNs, which bind to type I
interferon receptors and activate the Jak-STAT pathway to produce
antiviral proteins, the mRNA expression of IFN-δ is upregulated upon
viral infection by the same mechanism [6]. IFN-δ has been demon-
strated to have antiviral activity against Pseudorabies Virus (PRV),
Vesicular Stomatitis Virus (VSV), and Porcine reproductive and re-
spiratory syndrome virus (PRRSV) [6,7].
Different porcine interferon (PoIFN)-δ-related subtypes show dis-
tinct antiviral activities. The difference in these activities is likely
caused by the structure of the protein. For example, an unstable 4-α-
helix barrel can impair the function of IFN-δ. Among the three PoIFN-δ
subtypes, which include PoIFN-δ4, PoIFN-δ5, and PoIFN-δ8, the PoIFN-
δ8 has the strongest antiviral and immunomodulatory activities [6]. In
addition, researchers revealed that the porcine IFN-δ family comprises a
large number of members and the inner diversity is bigger than PoIFN-α
and PoIFN-ω families [6]. This phenomenon indicates their biological
importance, and it is prudent to explore whether IFN-δ could serve as a
therapeutic candidate, or alternative to other interferons for the treat-
ment of various viral diseases, such as foot and mouth disease (FMD).
Foot-and-mouth disease is an economically important and highly
contagious disease in cloven-hoofed animals, including cattle, swine,
and sheep [8]. The etiological agent, namely FMDV, is a prototypical
member of the Aphthovirus genus of the family, Picornaviridae. How-
ever, this virus exists in seven serotypes (namely A, O, C, Asia1, SAT1,
https://doi.org/10.1016/j.intimp.2018.03.022
Received 28 February 2018; Received in revised form 5 March 2018; Accepted 20 March 2018
⁎ Corresponding authors at: State Key Laboratory of Veterinary Etiological Biology, National, Foot-and-Mouth Diseases Reference Laboratory, Lanzhou Veterinary Research Institute,
Chinese Academy of Agricultural Sciences, Lanzhou 730046, PR China.
E-mail addresses: changhuiyun@caas.cn (H.-y. Chang), zhangyongguang@caas.cn (Y.-g. Zhang).
International Immunopharmacology 59 (2018) 47–52
Available online 03 April 2018
1567-5769/ © 2018 Published by Elsevier B.V.
T
SAT2, and SAT3) and multiple subtypes that do not cross-protect
against each other, making it difficult to effectively control the disease
[9,10]. Given its antigenic variability, the use of FMD vaccines to
protect early infection is limited. Therefore, an alternative strategy of
applying antiviral agents is required to control the spread of FMDV
during outbreaks. In recent years, the World Organization for Animal
Health (OIE) has suggested that an effective disease control program
should use newly developed vaccines alongside antiviral or im-
munomodulatory agents [11]. Herein, PoIFN-δ8 was expressed and
purified in a prokaryotic expression system, and its in vitro antiviral
activity against FMDV was investigated using IBRS-2 cells.
2. Materials and methods
2.1. Cells and viruses
The FMDVs (O/MYA98/BY/2010 and A/GD/MM/2013) were pre-
served and provided by OIE/National Foot-and-Mouth Disease
Reference Laboratory of China. Swine kidney cells (IBRS-2) were pur-
chased from CCTCC (China Center for Type Culture Collection) and
then maintained in our laboratory. IBRS-2 cells were cultured in
Dulbecco's Modified Eagle Medium (DMEM) (Gibco, Grand Island, NY)
containing 10% fetal bovine serum (FBS) at 37 °C and 5% CO2.
Escherichia coli (E. coli) Rosetta (DE3) Lys cells were used for expression
of PoIFN-δ8. The TCID50 of FMDV was calculated according to the Reed
and Muench method [12].
2.2. Cloning, expression and purification of PoIFN-δ8
The PoIFN-δ8 gene (Gene accession GQ415081) lacking the signal
sequence was codon-optimized for Escherichia coli expression (the op-
timized sequence is listed in S1) and synthesized by Shanghai Sangon
Biotechnology Co., Ltd. (Shanghai, China). The vector containing the
target gene flanked by EcoRI and Hind III restriction sites, was digested
with the corresponding enzymes and ligated into the same sites in a
pET-30a expression vector (Novagen, Corporation, CA, USA) to gen-
erate pET30a-PoIFN-δ8. The gene contained an N-terminal His tag to
facilitate protein purification. The positive pET30a-PoIFN-δ8 clone was
induced with isopropyl β-D-thiogalactoside (Sigma, USA) in E. coli
Rosetta (DE3) Lys cells until the optical density (OD) at
600nm=0.4–0.6. After that time, growth continued for an additional
8 h. Subsequently, whole cells were collected and sonicated (at 200W,
2 s on and 2 s off) until the solution became clear. Supernatants and
sedimentations were then isolated by centrifugation. The inclusion
bodies were resuspended in Buffer A (8M urea, 2 mM β-mercap-
toethanol, 20mM Tris–HCl, 100mM NaH2PO4·2H2O pH=8.0), and
incubated at 4 °C for 16 h. Subsequently, the soluble protein was then
purified by Ni–NTA affinity chromatography using an AKTA purifier
FPLC (GE Healthcare), according to the manufacturer's instructions.
Briefly, the resuspended inclusion bodies was mixed with Ni–NTA
agarose matrix pre-equilibrated with Binding buffer (20mM Tris-HCl,
100mM NaH2PO4·2H2O, 6M Urea, pH 8.0), and then mixed gently by
shaking at 4 °C for 3 h. The lysate-Ni2+-NTA mixture was loaded onto a
column, and the column was then washed with Wash buffer (20mM
Tris-HCl, 100mM NaH2PO4·2H2O, 6M Urea, 80mM imidazole, pH 8.0).
Finally, the bound protein was eluted with Elution buffer (20mM Tris-
HCl, 100mM NaH2PO4·2H2O, 6M Urea, 500mM imidazole, pH 8.0).
Next, the purified protein was renatured through dialysis with buffer
(100mM Tris, 2 mM EDTA, 1% Glycine, 5% Glycerinum, pH 8.0) under
a urea gradient to reduce the concentration from 4M to 0M. After
denaturation and renaturation, soluble homogeneous protein was ob-
tained and the concentration was quantified using the Bradford Protein
Assay kit (Beyotime, Shanghai China), according to the manufacturer's
instructions. Endotoxin levels of the purified PoIFN-δ8 protein were
evaluated with Genscript ToxinSensor™ Chromogenic LAL Endotoxin
Assay Kit (New Jersey, USA) as described by the manufacturer.
2.3. Western blotting
Western blot was employed to confirm the expression of the His-
PoIFN-δ8. Briefly, 20 μg of recombinant His-PoIFN-δ8 was subjected to
12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE), followed by transfer to PVDF membranes and blocking with 5%
(w/v) nonfat milk for 1 h at room temperature (RT). After washing
three times with Tris-buffered saline-Tween solution (TBST), the
membranes were incubated with anti-poly histidine antibody (Sigma)
(diluted at 1:4000) overnight at 4 °C. After washing three times with
TBST, the membranes were incubated in rabbit anti-mouse His (ZSGB,
Beijing, China, diluted at 1:5000) for 1 h at RT. After being washed
three times in TBST, the ECL and a chemiluminescence kit were used for
imagining (Millipore Corporation, Billerica, MA, United States).
2.4. Anti-viral activities of pre- and post-treatment with PoIFN-δ8 in IBRS-2
cells
IBRS-2 cells were added to each well of a 96-well plate at a density
of 3.5× 104 cells/well (80% confluence). Two types of anti-viral
methods were used to investigate the effectiveness of PoIFN-δ8. In the
first method, cells were treated with a 10-fold serial dilution of PoIFN-
δ8 for 24 h and then infected with 100 TCID50 FMDV O/MYA98 for 1 h
(pre-treatment). The IBRS-2 cells were incubated at 37 °C and 5% CO2
in an incubator for 48 h until the maximum CPE of FMDV was reached.
In the second method, cells were infected with 100 TCID50 FMDV O/
MYA98 for 1 h and then treated with 2000 ng/ml, which was the lowest
concentration that provided 100% protection against CPE in the above-
mentioned concentration determination study at various time intervals
(0, 2, 4, 8, 16, and 24 h) (post-treatment). Untreated control wells (cell
control and virus control) were also maintained along with the treated
cells. When the virus control wells showed 100% CPE, the supernatants
were removed and the cells were added to MTS assay solution to detect
the level of viability of the infected cells using the CellTiter 96 AQueous
One Solution Proliferation Assay (Promega, USA). Quantitative real-
time RT-PCR with specific primers (FF: 5′-CCCAGGGCCACCACATAG-3′
and FR: 5′-AGCTTGTACCAGGGTTTGGC-3′) was used to measure the
relative viral mRNA expression levels in treated (test) and untreated
(control) wells. β-Actin (β-actin-F-5′-GACCACCTTCAACTCGATCA-3′
and β-actin-R-5′-GTGTTGGCGTAGAGGTCCTT-3′) was used as the re-
ference gene.
2.5. Antiviral activity of PoIFN-δ8 against different strain of FMDV
A pilot study was conducted according to the method described by
Usharani et al. [13] to calculate the optimal concentration of IFN pre-
treatment needed to protect cells from CPE prior to infection with
different strains of FMDV. In this study, IBRS-2 cells were treated with
different concentrations of PoIFN-δ8 (1000, 2000, 3000, and 4000 ng/
ml) for 24 h and were subsequently infected with 100 TCID50 of FMDV
A/GD/MM/2013. The cell viability and viral mRNA levels were as-
sessed as described above.
2.6. Evaluation IFN-stimulated genes (ISGs) expression in IBRS-2 cells
In order to elucidate the mechanism of PoIFN-δ8 antiviral efficacy,
IFN-stimulated genes (ISGs) expression in IBRS-2 cells were in-
vestigated by real time PCR. Briefly, IBRS-2 cells were plated on 12-well
plates at a density of 3.5× 105 per well and grown until 90% confluent.
And then, the cells were treated with 2000 ng/ml of PoIFN-δ8 for 24 h,
untreated cells as control group. Inocula were then removed, and cells
were washed twice with DMEM. Subsequently total cellular RNA was
extracted using the RNA Extraction Kit (Tiangen, Beijing, China) and
reverse-transcribed to cDNA with RT primer Mix provided in the
PrimeScriptTM RT reagent kit containing gDNA Eraser (Takara, Dalian,
China). Real-time PCR was used to analyse the expressions of ISG genes
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(including Mx1, ISG15, PKR, OAS) on an Agilent Technologies
Stratagene Mx3005P instrument (Agilent, USA) using SYBR Premix Ex
TaqTM II (Tli RNaseH Plus) (TaKaRa, Dalian, China). The following
primer sets were used for real-time PCR: porcine PKR forward,
5′-AAAGCGGACAAGTCGAAAGG-3′; porcine PKR reverse, 5′-TCCACTT
CATTTCCATAGTCTTCTGA-3′; porcine OAS forward, 5′-GAGCTGCAG
CGAGACTTCCT-3′; porcine OAS reverse, 5′-TGCTTGACAAGGCGGA
TGA-3′; porcine Mx1 forward, 5′-GGCGTGGGAATCAGTCATG-3′; por-
cine Mx1 reverse, 5′-AGGAAGGTCTATGAGGGTCAGATCT-3′; porcine
ISG15 forward, 5′-GCCCTCTCCAGTGCCCGG-3′; porcine ISG15 reverse,
5′-CCCAGGGCCACCACATAG-3′. β-Actin was used as the reference gene
[14]. Real-time PCR reactions were performed in a total volume of
25 μL containing template cDNA, forward and reverse primers, and
2× SYBR Premix Ex Taq (TaKaRa). The mRNA levels of ISG genes in
PoIFNδ8-treated cells or untreated cells were normalized to that of
porcine β-actin mRNA. Three independent experiments were per-
formed, and the average of the normalized values were presented.
2.7. Statistical analysis
The relative mRNA expression was calculated using the 2−ΔΔCT
method. All the graphical illustrations were conducted by GraphPad
Prism software. The significance of the differences was determined by
the t-test and one-way ANOVA using the SPSS software, followed by
Tukey's post-hoc multiple comparison test. All data are reported as
means ± standard deviation (n≥ 3). Values of p < 0.05 were con-
sidered statistically significant.
3. Results
3.1. Cloning and purification of PoIFN-δ8
In order to achieve a high protein yield, the nucleotide sequence of
the IFN-δ8 gene was optimized using high-usage E. coli codons. The
codon-optimized sequence was ligated into the expression vectors, and
recombinant plasmids were constructed (Fig. 1) and verified by DNA
sequencing (data not shown). The recombinant plasmid was then
transformed into E. coli Rosetta (DE3) Lys cells for expression. SDS-
PAGE analysis revealed that recombinant PoIFN-δ8 was mainly ex-
pressed as inclusion bodies, which exhibited a molecular weight of
22.87 kDa (Fig. 2A). Over 90% purity of rHis-PoIFN-δ8 protein was
obtained following purification with a Ni-NTA agarose (IMAC) column
(Fig. 2A) and the protein was confirmed by western blot analysis using
an anti-histidine monoclonal antibody (Fig. 2B). The concentration of
the purified PoIFN-δ8 was 793.6 μg/ml, while the endotoxin level of the
protein was assayed using the Genscript ToxinSensor™ Chromogenic
LAL Endotoxin Assay Kit (New Jersey, USA) and found to be lower than
0.01 EU/ml.
3.2. Antiviral activity of PoIFN-δ8
To evaluate the minimum antiviral protection concentration of
PoIFN-δ8 for IBRS-2 cells, PoIFN-δ8 was serially diluted ten-fold from
2000 to 0.02 ng/ml and five replicates were added to naïve cells. The
cells were challenged with FMDV O/MYA98 24 h post-PoIFN-δ8 treat-
ment. The highest dilution of PoIFN-δ8 to protect IBRS-2 cells from
FMDV-induced CPE was 2000 ng/ml, which showed 100% protection.
Other dilutions of PoIFN-δ8 tested did not confer protection to the cells
from CPE caused by FMDV O/MYA98 (Fig. 3A). There was a significant
difference in the CPE effect between the 2000 ng/ml group and the
other concentration and virus control groups (p < 0.01). A con-
centration of 2000 ng/ml reduced viral mRNA levels by 4.63-log titers,
compared to virus controls (Fig. 3B). To evaluate whether PoIFN-δ8
could prevent CPE of cells following viral infection, the antiviral effi-
cacy of PoIFN-δ8 was evaluated at various intervals post-FMDV infec-
tion. IBRS-2 cells were infected with FMDV O/MYA98 at various time
intervals (0, 2, 4, 8, 16 and 24 h) and treated with 2000 ng/ml of PoIFN-
δ8, which was the lowest concentration that provided 100% protection
against CPE. PoIFN-δ8 demonstrated 100% protection against FMDV-
induced CPE for up to 8 h post-infection (Fig. 4A) and showed a 4.17-
log to 4.85-log reduction in viral mRNA levels at 0, 2, and 4 h post-
infection, compared to virus controls (Fig. 4B) (p < 0.01). However, no
protection was observed against CPE and viral mRNA levels were not
decreased at 16 h or 24 h post-FMDV infection (Fig. 4B), compared to
CPE and viral mRNA levels, respectively, in the non-treated group
(Non-tr) (p > 0.05).
3.3. Antiviral activity of PoIFN-δ8 against type A FMDV
To investigate the potential broad-spectrum antiviral activity of
PoIFN-δ8, IBRS-2 cells was pre-treated with different concentrations of
PoIFN-δ8 for 24 h. Cells were then infected with 100 TCID50 FMDV A/
GD/MM/2013. PoIFN-δ8 (1000 ng/ml) showed at or near 100% pre-
vention of CPE caused by type A FMDV (Fig. 5).
3.4. PoIFN-δ8-induced expression of ISGs
Type I IFNs exhibit antiviral activity by binding specific receptors
and stimulating hundreds of downstream ISG genes. PoIFN-δ8 also in-
duced the expression of Mx1, ISG15, PKR and OAS1 genes by 149.17-
fold, 119.16-fold, 3.7-fold and 328-fold, respectively, compared to cells
without IFN treatment (Fig. 6).
4. Discussion
Generally, IFNs constitute the first step in the immune response
against viral infection, and have been used to fight cancer or viral in-
fections. In terms of FMDV, previous studies demonstrated that type I
IFNs (including IFN-α, β, τ), IFN-γ and IFN-λ had certain antiviral ac-
tivities against FMDV [11,13,15,16]. In our recent study, we demon-
strated that IFN-ω had antiviral activities against foot and mouth dis-
ease virus (unpublished). However, interferon delta, which is a type I
IFN, has never been investigated in this capacity. This is the first study
to assess the anti-FMDV activity of PoIFN-δ in cells using MTS assays
and RT-PCR to evaluate the reduction in cytopathic effects and viral
mRNA levels after FMDV infection. Similar to the case in IFN-ω,
Fig. 1. Recombinant pET30a-PoIFN-δ8 plasmid construction. The PoIFN-δ8
sequence was inserted into the vectors at the EcoRI and Hind III restriction sites.
Plasmid pET30a-PoIFN-δ8 consisted of a His tag and the mature PoIFN-δ8 se-
quence.
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Fig. 2. A. SDS-PAGE analysis of PoIFN-δ8 expres-
sion: Lane M: Protein marker; Lane 1: Uninduced
control; Lane 2: Induced protein in soluble fraction;
Lane 3: Induced protein in inclusion bodies; Lane 4:
Purified and dialyzed PoIFN-δ8. 2B. Western blot
confirmation of PoIFN-δ8 using anti-polyhistidine
monoclonal antibody. Lane M: Protein marker; Lane
1: Purified PoIFN-δ8 protein.
Fig. 3. Concentration dependent antiviral activity of PoIFN-δ8. 3A. CPE reduction by PoIFN-δ8 in IBRS-2 cells. 3B. FMDV mRNA expression reduction by PoIFN-δ8 in
IBRS-2 cells. IBRS-2 cells were pretreated with 10-fold dilutions of PoIFN-δ8 for 24 h before infection with FMDV O/MYA98. The percent inhibition of CPE was
calculated as 100× [OD650 (each sample)-OD650 (virus control)/OD650 (cell control)-OD650 (virus control)]. VC (viral control) indicates the IBRS-2 cells infected
with O/MYA98, and without PoIFN-δ8. CC (cell control) indicates the non-treated IBRS-2 cells. The graph represents three independent experiments with five
replicates in each experiment. Data were analyzed by t-test and one way ANOVAs, followed by Tukey's post-hoc test. **p < 0.01 compared with the non-treated
control.
Fig. 4. Post-infection antiviral activity of PoIFN-δ8 against FMDV O/MYA98. 4A. Protection from CPE in IBRS-2 cells after infection with FMDV O/MYA98.
Protection was expressed as the percent protection, compared to untreated virus. 4B. The reduction of mRNA levels following treatment with PoIFN-δ8, after
infection with FMDV O/MYA98 (post-infection therapy). IBRS-2 cells were infected with FMDV O/MYA98 and treated with PoIFN-δ8 at 0, 2, 4, 8, 16 and 24 h post-
infection. Untreated virus and cell controls were also maintained. Non-tr indicates IBRS-2 cells infected with O/MYA98, and without PoIFN-δ8 treatment. The graph
represents at least three independent experiments with five replicates in each experiment. The values are represented as the mean ± SD. Data were analyzed by t-test
and one way ANOVAs, followed by Tukey's post-hoc test. **p < 0.01 compared with the control group.
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different subtypes of IFN-δ exhibit various antiviral and cross-species
activity. For example, Zhao et al., [6] demonstrated that PoIFN-δ8 had
the strongest antiviral and immunomodulatory activities. In this article,
PoIFN-δ8 was expressed and its biological activities against FMDV was
investigated. Our data demonstrated that PoIFN-δ8 had antiviral ac-
tivities against FMDV. In pre-infection experiments, 2000 ng/ml of
PoIFN-δ8 was the lowest concentration to provide 100% protection of
IBRS-2 cells from CPE caused by infection with FMDV O/MYA98. It also
provided significant protection against CPE and exhibited a 2.91-log
reduction in viral RNA levels up to 8 h post-infection, compared to virus
controls (p < 0.01). An increased trend in viral mRNA levels was ob-
served from 0 to 8 h post-FMDV infection and elevated significantly
after 8 h. No dramatic cytopathic effects were observed during this
period. In general, it takes about 8 h for the FMDV to replicate com-
pletely. At that, PoIFN-δ8 treatment was no longer effective in de-
creasing viral mRNA levels or CPE, and caused further destruction to
host cells. These results suggest that PoIFN-δ8 could be useful as an
adjunct treatment during an FMD outbreak, as long as it is administered
at the onset of the outbreak to protect the unaffected herd, and that the
treatment is administered within 8 h of exposure to FMDV.
In this study, FMDV A/GD/MM/2013, a classical type A FMDV
strain in our country was investigated. We found that PoIFN-δ8 could
protect the cells from FMDV A/GD/MM/2013 infection, with a con-
centration of 1000 ng/ml needed to provide 100% protection of IBRS-2
cells. These results are comparable with the study from Usharani et al.,
[13] which showed that OvIFN-τ4 could also exhibit antiviral activities
against FMDV types O, A and Asia. These results revealed that IFNs
exert their antiviral activities against a wide variety of viruses, in-
dependent of the serotype or strain challenged.
Generally, type I interferons mediate the JAK/STAT pathway to
stimulate the production of antiviral effectors such as ISG genes, which
interfere with different stages of viral life cycles, and inhibit viral re-
plication or degrade viral components [17]. In this study, the expres-
sion levels of OAS1, ISG15, MX1, and PKR in PoIFNδ8-treated cells
were significantly higher than those of the untreated cells (p < 0.01).
Therefore, by activating the JAK-STAT signaling pathway, PoIFN-δ8
inhibited viral replication and exerted antiviral activity against FMDV.
Recently, there has been increasing interest in investigating the ef-
ficacy of combined IFN therapies, which has been shown to enhance
protection, compared to single IFN therapies [15,16,18]. In future
studies, it will be necessary to assess whether combining PoIFN-δ8 with
other interferons (e.g., IFN-γ) would lead to increased efficacies against
FMDV. Although the in vitro antiviral effects of IFN-ω were confirmed
against FMDV, we did not confirm the in vivo activities in this study.
Thus, future research is needed to investigate the efficacy of PoIFN-δ8
in animals and determine the true potential of PoIFN-δ8 as an adjunct
control measure in FMD outbreaks. Such studies are also necessary to
inform on the exact mechanisms leading to the biological activities of
PoIFN-δ8, and explore safer, new strategies to prevent this and other
diseases in pigs.
In conclusion, we demonstrated that PoIFN-δ8 exhibits antiviral
activities against FMDV by inducing ISG gene expression. These find-
ings enrich our knowledge of IFN-δ, and highlight the significance of
PoIFN-δ as an antiviral against FMDV.
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